Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bruce Berkowitz is Bullish About Eli Lilly $LLY

Bruce Berkowitz, founder and manager of the Fairholme fund has had a change of heart. Berkowitz has gone from bull to bear on pharmaceutical stocks.

FAIRHOLME (FAIRX) Bruce Berkowitz

Bruce Berkowitz Bullish on Pharmaceuticals in the First Quarter

Bruce Berkowitz was decidedly bullish on pharmaceutical stocks in the first quarter, buying new positions in several companies. Specifically, he bought a positions worth just over $7 million in each of these four pharmaceutical companies – AstraZeneca (AZN), Bristol Myers Squibb (BMY), GlaskoSmithKline (GSK) and Eli Lilly (LLY). The stocks did fairly well in the first two quarters of the year. AZN returned 12.46% from January to the end of June, BMY returned 26.49%, GSK returned 19.15% and LLY returned 13.93%. Each company returned 10 percentage points or more higher than the market – the SPY returned 2.69% over the same period.

Bruce Berkowitz Kept his LLY Position

Bruce Berkowitz decided to sell out of his pharmaceutical positions in the second quarter, all except one  according to GuruFocus – Eli Lilly (LLY). One possible reason for keeping LLY is its high dividend. The company offers 5.1% compared to the 4% offered by BMY, 4.9% by GSK and 3.2% by AZN. LLY also has one of the lower P/E ratios of the four, boasting 9.07 to BMY’s 16.59 and GSK’s 22.56, suggesting the stock could be underpriced. LLY also has the lowest enterprise value relative to its free cash flow at 6.84, compared to BMY’s 13.03, GSK’s 20.14 and AZN’s 8.04.